All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
GIMEMA AML1310 trial: 6-year update on risk-adapted, MRD-directed therapy for younger patients with AML
Bookmark this article
|
The multicenter, prospective, risk-adapted, MRD-oriented, phase II GIMEMA AML1310 trial (NCT01452646) assessed whether delivering post-remission therapy with risk-determined intensity, based on upfront genetic risk and post-consolidation MRD status, could improve outcomes in 500 patients aged 18–60 years with previously untreated AML.1 Post-consolidation therapy was chosen based on NCCN 2009 risk stratification and MRD status, with patients in the favorable-risk, intermediate-risk and MRD-negative, and intermediate-risk with no leukemia-associated immunophenotype groups receiving auto-HSCT, and patients in the poor-risk, and intermediate-risk and MRD-positive groups receiving allo-HSCT. 1 Following primary results from this trial, updated results, with a follow-up of 6 years, were published in Blood Advances by Venditti, et al.1 |
| Key learnings |
| Overall, 6-year OS and DFS rates were 42.7% and 41.9%, respectively. In the favorable-risk, poor-risk, intermediate-risk, and intermediate-risk with no LAIP groups, 6-year OS rates were 58.5%, 34.1%, 41.4%, and 32.5%, and 6-year DFS rates were 50.1%, 34.8%, 45%, and 29.1%, respectively, demonstrating the benefit of auto-HSCT in lower-risk patients, and the long-term survival benefit of allo-HSCT in higher-risk patients. |
| In the intermediate-risk group, where transplantation was allocated based on MRD status, 6-year OS rates were similar between patients who were MRD positive vs MRD negative (57.8% vs 57%), as were 6-year DFS rates (52.7% vs 46.6%), highlighting the utility of MRD-directed therapy in these patients. |
| A post hoc analysis demonstrated a 65.4% concordance with the ELN 2017 risk stratification, mainly in the favorable- and intermediate-risk categories, with post-consolidation MRD assessment remaining an important factor for intermediate-risk. |
| These updated 6-year results confirm the long-term benefit of a risk-adapted, MRD-directed post-remission treatment strategy in younger patients with previously untreated AML. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; auto-HSCT, autologous hematopoietic stem cell transplantation; DFS, disease-free survival; ELN, European LeukemiaNet; GIMEMA, Gruppo Italiano Malattie EMatologiche dell'Adulto; LAIP, leukemia-associated immunophenotype; MRD, measurable residual disease; NCCN, National Comprehensive Cancer Network; OS, overall survival.
- Venditti A, Piciocchi A, Candoni A, et al. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial. Blood Adv. 2024;8(16):4410-4413. DOI: 1182/bloodadvances.2024013182
Your opinion matters
15 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox